AU2005311975A1 - Compositions and methods for the treatment of autism - Google Patents

Compositions and methods for the treatment of autism Download PDF

Info

Publication number
AU2005311975A1
AU2005311975A1 AU2005311975A AU2005311975A AU2005311975A1 AU 2005311975 A1 AU2005311975 A1 AU 2005311975A1 AU 2005311975 A AU2005311975 A AU 2005311975A AU 2005311975 A AU2005311975 A AU 2005311975A AU 2005311975 A1 AU2005311975 A1 AU 2005311975A1
Authority
AU
Australia
Prior art keywords
composition
transglucosidase
group
amylase
carbohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005311975A
Other languages
English (en)
Inventor
Anthony Collier
Steven Marr
Rohit Medhekar
Larry Newman
Jon B. Pangborn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATIONAL ENZYME COMPANY Inc
Kirkman Group Inc
Original Assignee
National Enzyme Co Inc
Kirkman Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Enzyme Co Inc, Kirkman Group Inc filed Critical National Enzyme Co Inc
Publication of AU2005311975A1 publication Critical patent/AU2005311975A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01024—1,4-Alpha-glucan 6-alpha-glucosyltransferase (2.4.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C12N9/107—1,4-Alpha-glucan branching enzyme (2.4.1.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2005311975A 2004-12-01 2005-11-30 Compositions and methods for the treatment of autism Abandoned AU2005311975A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/000,668 US20060115467A1 (en) 2004-12-01 2004-12-01 Compositions and methods for the treatment of autism
US11/000,668 2004-12-01
PCT/US2005/043175 WO2006060414A2 (en) 2004-12-01 2005-11-30 Compositions and methods for the treatment of autism

Publications (1)

Publication Number Publication Date
AU2005311975A1 true AU2005311975A1 (en) 2006-06-08

Family

ID=36565652

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005311975A Abandoned AU2005311975A1 (en) 2004-12-01 2005-11-30 Compositions and methods for the treatment of autism

Country Status (8)

Country Link
US (2) US20060115467A1 (cg-RX-API-DMAC7.html)
EP (1) EP1817052A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008521906A (cg-RX-API-DMAC7.html)
CN (1) CN101287829A (cg-RX-API-DMAC7.html)
AU (1) AU2005311975A1 (cg-RX-API-DMAC7.html)
CA (1) CA2590384A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006060414A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200704677B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
EP2016838B1 (fr) * 2007-06-18 2017-05-31 ET & DS Company Ltd Supplément alimentaire
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20110097765A1 (en) * 2008-04-30 2011-04-28 Gang Duan Enhanced fermentation process using molasses
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
PL2318035T3 (pl) * 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
JP5684725B2 (ja) 2009-01-06 2015-03-18 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
EP2443259A4 (en) * 2009-06-16 2012-10-10 Univ Columbia BIOMARKERS FOR AUTISM AND USES THEREOF
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US9931381B2 (en) * 2009-11-23 2018-04-03 Prothera, Inc. Methods of comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
DK2701733T3 (da) 2011-04-21 2019-05-27 Curemark Llc Forbindelser til behandling af neuropsykiatriske forstyrrelser
KR20190109564A (ko) * 2012-01-03 2019-09-25 큐어마크, 엘엘씨 신경계 및 정신 장애의 행동 증상을 치료하는 방법
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10195256B2 (en) 2015-12-14 2019-02-05 Thea Fournier Enzyme formulation for reducing salicylate and other intolerance
US9775887B2 (en) * 2015-12-14 2017-10-03 Thea Fournier Enzyme formulation for reducing salicylate intolerance
CN105652016A (zh) * 2016-01-28 2016-06-08 深圳大学 一种孤独症检测标志物及其检测方法
GB201614415D0 (en) 2016-08-24 2016-10-05 Pepsis Ltd Enzymes for the treatment of human enterometabolic dysfunction
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
TWI658791B (zh) * 2017-09-25 2019-05-11 愛之味股份有限公司 具有調節血脂、改善腸道菌叢及提升免疫力功能的富含寡醣乳製品及其製法
WO2020169545A1 (en) * 2019-02-19 2020-08-27 Dsm Ip Assets B.V. Method for reducing fructan in a food product with aid of invertase (ec 3.2.1.26)
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
EP4452302A4 (en) * 2021-12-23 2026-04-08 Access Nutrients Inc PREVENTION AND TREATMENT OF DISEASES USING A PHYTASE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042823A (en) * 1998-07-02 2000-03-28 Amano Pharmaceuticals Co., Ltd. Enzyme composition and use thereof
US6783757B2 (en) * 2000-06-01 2004-08-31 Kirkman Group, Inc. Composition and method for increasing exorphin catabolism to treat autism
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions

Also Published As

Publication number Publication date
EP1817052A4 (en) 2008-07-02
CA2590384A1 (en) 2006-06-08
US20080112944A1 (en) 2008-05-15
US20060115467A1 (en) 2006-06-01
WO2006060414A2 (en) 2006-06-08
CN101287829A (zh) 2008-10-15
EP1817052A2 (en) 2007-08-15
JP2008521906A (ja) 2008-06-26
ZA200704677B (en) 2008-09-25
WO2006060414A3 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
US20080112944A1 (en) Compositions and methods for the treatment of autism
US9498520B2 (en) Use of proteases for gluten intolerance
US6783757B2 (en) Composition and method for increasing exorphin catabolism to treat autism
US6051220A (en) Composition to improve digestibility and utilization of nutrients
US5445957A (en) Enzyme food supplement composition containing beta-fructofuranosidase, cellulase and hemicellulase
Lin et al. Direct starch digestion by sucrase-isomaltase and maltase-glucoamylase
US20040057944A1 (en) Microbial enzyme mixtures useful to treat digestive disorders
US20140342042A1 (en) Method of lowering glycemic index of foods
US10159721B2 (en) Enzyme formulation for use as food supplement
Nilsson et al. Hydrolysis of lactitol, maltitol and Palatinit® by human intestinal biopsies
CA2055506C (en) Composition and method for reducing gastro-intestinal distress due to alpha-d-galactoside-linked/containing sugars
JP2019189647A (ja) α−グルコシダーゼに関連付けられる病的状態の予防及び/又は治療のための組成物
Zárate et al. Feeding with dairy Propionibacterium acidipropionici CRL 1198 reduces the incidence of Concanavalin-A induced alterations in mouse small intestinal epithelium
Sequeira et al. Lactose intolerance: genetics of lactase polymorphisms, diagnosis and novel therapy
Fara et al. In vitro digestibility of oligosaccharides synthesized by dairy propionibacteria β-galactosidase from lactose, lactulose and lactitol
US20090060956A1 (en) Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity)
EP3079495B1 (en) Medicament and method for treating innate immune response diseases
CA3230687A1 (en) Fungal enzyme mixtures and uses thereof
JP2024101018A (ja) 経口用組成物
AU2013211517A1 (en) Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity)
Reif et al. Carbohydrates in infant nutrition
Lin et al. Unexpected high digestion rate of cooked starch by the Ct-Maltase-Glucoamylase small intenstine mucosal a-Glucosidase subunit
Las PC Digestive Enzymes
Lin et al. Unexpected High Digestion Rate of Cooked Starch by the Ct-Maltase
Simsek Inhibition of activities of individual subunits of intestinal Maltase-Glucoamylase and Sucrase-Isomaltase by dietary phenolic compounds for modulating glucose release and gene response

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application